Subscribe to Newsletter
Business & Profession Professional Development

This Month in Business

  • The FDA have approved Genentech’s pre-filled ranibizumab 0.5 mg syringe for the treatment of patients with wet age-related macular degeneration and macular edema after retinal occlusion. The syringe is expected to be available in early 2017.
  • Envisia Therapeutics has released interim results from its ongoing 12 month Phase II study assessing a single administered dose of extended-release travoprost in five patients with glaucoma. Results demonstrate a 26 percent decrease in IOP nine months after administration.  
  • The FDA have approved Genentech’s pre-filled ranibizumab 0.5 mg syringe for the treatment of patients with wet age-related macular degeneration and macular edema after retinal occlusion. The syringe is expected to be available in early 2017.
  • Envisia Therapeutics has released interim results from its ongoing 12 month Phase II study assessing a single administered dose of extended-release travoprost in five patients with glaucoma. Results demonstrate a 26 percent decrease in IOP nine months after administration.  
  • Allegro Ophthalmics has announced topline results from its Phase IIb DEL MAR trial evaluating ALG-1001 (Luminate versus bevacizumab monotherapy in patients with diabetic macular edema. Both the primary and secondary endpoints (non-inferiority to bevacizumab in best-corrected visual acuity and mean change in central macular thickness, respectively) were met at 20 weeks.
  • HOYA announced an agreement to acquire Performance Optics and its subsidiaries VISION EASE and Daemyung Optical, expanding the Japanese company’s global reach.
  • Abbott announced Q3 2016 sales of $5.3 billion. Sales for medical optics totaled $296 million – an increase of four percent on an operational basis which the company attributed to cataract products in their premium IOL segment. Johnson & Johnson is expected to complete acquisition of Abbot Medical Optics in early 2017.  
  • Novaliq has appointed Christian Roesky as CEO, effective November 1, 2016. Bernhard Günther – the former CEO – will commence the new role of Chief Innovation Officer. 
  • Steven Schallhorn has been appointed Chief Medical Officer for Global Ophthalmic Devices at Carl Zeiss Meditech. 
Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Ruth Steer
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: